This funding opportunity supports preclinical and patient-based research to understand how incretin mimetics, including GLP-1, GIP-1, or dual agonists/antagonists, impact cancer risk. The focus is on mechanistic studies rather than clinical trials or short-term effects such as weight loss and diabetes. Research aims to clarify the dual role of these agents in increasing or decreasing risk for obesity-related cancers.
Eligible applicants include a wide range of organizations such as independent school districts, higher education institutions, for-profit and nonprofit organizations, tribal governments, small businesses, and various federally recognized and community-based entities. Non-U.S. entities and regional o
